NuCana

NCNAPhase 3

Edinburgh, United Kingdomnucana.com

NuCana is a UK-based, publicly traded biopharma company focused on transforming widely prescribed chemotherapy agents using its phosphoramidate-based ProTide technology. Its mission is to significantly improve survival outcomes for cancer patients by developing more effective and safer medicines. The company has a clinical-stage pipeline targeting various solid tumors and hematological malignancies, and is led by a management team with extensive drug development and commercialization expertise.

Market Cap

$6.9M

Focus

Small Molecules

AI Company Overview

Technology Platform

Proprietary ProTide technology, a phosphoramidate chemistry platform designed to transform established nucleoside analog chemotherapy agents into more effective and safer medicines by improving intracellular activation and delivery.

Pipeline Snapshot

7 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
NUC-1031 + Gemcitabine + Cisplatin	Biliary Tract Cancer	Phase 3
Fosifloxuridine Nafalbenamide + Leucovorin + Irinotecan + Bevacizumab + 5-FU	Colorectal Cancer	Phase 2
NUC-1031 500 mg + NUC-1031 750mg	Ovarian Cancer	Phase 2
Fosifloxuridine Nafalbenamide + Leucovorin + Pembrolizumab + Docetaxel	Advanced Cancer	Phase 1/2
NUC-3373 + leucovorin + NUC-3373 + NUFOX + NUFOX + VEGF pathway inhibitor + NUFO...	Colorectal Cancer	Phase 1/2

Funding History

Total raised: $182M

PIPE$25MUndisclosedJun 15, 2020

IPO$100MUndisclosedSep 28, 2017

Series B$37MMorningside VenturesJun 15, 2015

Series A$20MMorningside VenturesJun 15, 2013

Opportunities

NuCana's primary growth opportunity lies in successfully advancing NUC-3373 as a potential best-in-class successor to 5-FU in the large colorectal cancer market and developing NUC-7738 as a novel therapy for the growing population of patients with immunotherapy-resistant cancers.

Validating the ProTide platform could also enable partnerships or new internal programs.

Risk Factors

Key risks include clinical trial failure, high cash burn with dependence on volatile equity markets for funding, intense competition in oncology, and the platform-centric nature of the company's value proposition.

Negative data for lead candidates could be catastrophic.

Competitive Landscape

NuCana competes with generic chemotherapy, targeted therapies, immunotherapies, and other next-generation cytotoxic developers. Its differentiation is the ProTide platform's potential to create significantly improved versions of proven chemotherapy backbones, aiming for rapid adoption within established treatment paradigms.